Stati Uniti - Ingliż - NLM (National Library of Medicine)

a-s medication solutions - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 10 mg in 1 ml

Stati Uniti - Ingliż - NLM (National Library of Medicine)

henry schein - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lidocaine and epinephrine injection, usp is indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. lidocaine and epinephrine injection is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

septodont, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lignospan solutions are indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. lignospan is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

patterson dental - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lidocaine and epinephrine injection, usp is indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. lidocaine and epinephrine injections is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

septodont, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 20 mg in 1 ml - lignospan solutions are indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. lignospan is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

benco dental - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride 20 mg in 1 ml - lidocaine and epinephrine injection, usp is indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. lidocaine and epinephrine injections is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - bicisate dihydrochloride, quantity: 0.9 mg - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; monobasic sodium phosphate; water for injections - [99mtc]-bicisate scintigraphy is indicated in the evaluation and localisation of regional perfusion abnormalities in adult patients with the central nervous system disorders of stroke and dementia.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

us medsource, llc - lidocaine hydrochloride anhydrous (unii: ec2cnf7xfp) (lidocaine - unii:98pi200987), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride and epinephrine injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

qpharma inc - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)] . risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiological studies reporting on pregnancies exposed to meclizine have not identified an association between the use of meclizine during pregnancy and an increased risk of major birth defects. animal data in a published study, oral administration of meclizine (25 mg/kg to 250 mg/kg) to pregnant rats during the period of organogenesis resulted in a high incidence of fetal malformations. these effects occurred at doses as low as 25 mg/kg, which is approximately 2 times the maximum recommended human dose (100 mg) on a body surface area (mg/m 2 ) basis. risk summary there are no data on the presence of meclizine in human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for meclizine hydrochloride and any potential adverse effects on the breastfed infant from meclizine hydrochloride or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. the effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. as meclizine hydrochloride undergoes metabolism, hepatic impairment may result in increased systemic exposure of meclizine. treatment with meclizine hydrochloride should be administered with caution in patients with hepatic impairment. the effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. because of a potential for drug/metabolite accumulation, meclizine hydrochloride should be administered with caution in patients with renal impairment and in the elderly, as renal function generally declines with age. the genetic polymorphism of cyp2d6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure. therefore, when meclizine hydrochloride is administered to patients with cyp2d6 polymorphism, monitor for adverse reactions and clinical effect accordingly.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system. meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.